|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Supplemental Table 1 | IBD and negative GI paneln= 54 | IBD and any pathogenn= 38 | p-value | Clostridioides difficilen= 14 | Escherichia coli subtypen= 15 | Norovirusn= 9 |
| Female  | 29 (53.7%) | 17 (44.7%) | 0.397 | 4 (28.6%) | 10 (66.7%) | 3 (33.3%) |
| Age at test (years; median, IQR) | 36 (27.8-55.4) | 34 (26.6-43.3) | 0.300 | 32.5 (26.6-46.4) | 33.2 (26.9-43.3) | 37.1 (24.4-42.3) |
| IBD Crohn’s disease Ulcerative colitis | 29 (53.7%)25 (46.3%) | 12 (31.6%)26 (68.4%) | 0.036 | 4 (28.6%)10 (71.4%) | 5 (33.3%)10 (66.7%) | 3 (33.3%)6 (66.7%) |
| Montreal classification CD A1- Age <17 A2- Age 17-40 A3- Age >40 L1- Ileal L2- Colonic L3- Ileocolonic B1- Inflammatory B2- Stricturing B3- Penetrating Perianal | 11 (20.4%)12 (41.4%)6 (11.1%)6 (11.1%)5 (9.3%)18 (33.3%)11 (20.4%)1 (1.9%)17 (31.5%)7 (13%) | 3 (7.9%)6 (15.8%)3 (7.9%)3 (7.9%)3 (7.9%)6 (15.8%)2 (5.3%)2 (5.3%)8 (21.1%)2 (5.3%) |  0.6090.8190.1600.221 | 04 (28.6%)01 (7.1%)1 (7.1%)2 (14.3%)1 (7.1%)03 (21.4%)2 (14.3%) | 2 (13.3%)1 (6.7%)2 (13.3%)2 (13.3%)03 (20%)1 (6.7%)2 (13.3%)2 (13.3%)0 | 1 (11.1%)1 (11.1%)1 (11.1%)0 2 (22.2%)1 (11.1%)003 (33.3%)0 |
| Montreal classification UC E1- Proctitis E2- Left-sided colitis E3- Extensive colitis | 5 (9.3%)5 (9.3%)15 (27.8%) | 5 (13.2%)7 (18.4%)14 (36.8%) | 0.693 | 2 (14.3%)2 (14.3%)6 (42.9%) | 3 (20%)2 (13.3%)5 (33.3%) | 03 (33.3%)3 (33.3%) |
| Duration of IBD (years; median, IQR) | 7.9 (1.3-16.5) | 10.5 (2.5-13.9) | 0.621 | 8.4 (1.5-13.8) | 11.5 (3.3-14.3) | 10.5 (3.6- 13.3) |
| IBD therapies at test Systemic steroids Topical steroids 5-ASA Anti-TNF Anti-Integrin  Anti-IL 12/23 JAK inhibitor Immunomodulator None | 13 (24.1%)4 (7.4%)13 (24.1%)10 (18.5%)2 (3.7%)6 (11.1%)1 (1.9%)3 (5.6%)14 (25.9% | 3 (7.9%)5 (13.2%)16 (42.1%)5 (13.2%)4 (10.5%)003 (7.9%)11 (28.9%) | 0.0440.3610.0670.4930.1920.0340.3990.6550.748 | 2 (14.3%)07 (50%)2 (14.3%)1 (7.1%)001 (7.1%)3 (21.4%) | 04 (26.7%)6 (40%)2 (13.3%)3 (20%)001 (6.7%)4 (26.7%) | 1 (11.1%)1 (11.1%)3 (33.3%)1 (11.1%)0001 (11.1%)4 (44.4%) |
| Place of test Emergency department Inpatient Outpatient | 9 (16.7%)32 (59.3%)13 (24.1%) | 8 (21.1%)15 (39.5%)15 (39.5%) | 0.159 | 1 (7.1%)8 (57.1%)5 (25.7%) | 2 (13.3%)4 (26.7%)9 (60%) | 5 (55.6%)3 (33.3%)1 (11.1%) |
| Symptoms  Diarrhea Bloody diarrhea Hematochezia Abdominal pain Fever Nausea/vomiting Other | 12 (22.2%)19 (35.2%)2 (3.7%)31 (57.4%)13 (24.1%)12 (22.2%)7 (13%) | 26 (68.4%)9 (23.7%)3 (7.9%)23 (60.5%)5 (13.2%)16 (42.1%)5 (13.2%) | 0.0010.2380.3830.7650.1940.0410.978 | 10 (71.1%)5 (35.7%)08 (57.1%)1 (7.1%)4 (28.6%)2 (14.3%) | 9 (60%)4 (26.7%)3 (20%)8 (53.3%)2 (13.3%)3 (20%)3 (20%) | 7 (77.9%)007 (77.8%)2 (22.2%)9 (100%)0 |
| Inflammatory biomarkers (median, IQR) C-rp (mg/L) ESR (mm/hr) | 28 (5.4-94)57 (23-85) | 11.3 (2-47.6)12 (8-28) | 0.0880.014 | 12.6 (1.4-74)26 (12-86) | 6.7 (2.8-14.4)8 (5-50) | 37.2 (21.4-57.9)11 (9-12) |

Abbreviations: IBD- inflammatory bowel disease; IQR- interquartile range; 5-ASA- aminosalicylates; TNF- tumor necrosis factor; IL- interlukin; JAK- Janus kinase; C-rp- C-reactive protein; ESR- sedimentation rate.